{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Addyi (Drug)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Sprout Pharmaceuticals Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Philidor Rx Services LLC", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Ackman, William A", "name": "persons", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/10/business/female-viagra-addyi-valeant-dysfunction.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}, {"lastname": "MORGENSON", "firstname": "Gretchen", "role": "reported", "organization": "", "rank": 2}], "original": "By KATIE THOMAS and GRETCHEN MORGENSON"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg", "legacy": {"wide": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbWide-v2.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg", "legacy": {"xlarge": "images/2016/04/10/business/10SPROUT/10SPROUT-articleLarge-v2.jpg", "xlargeheight": "330", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 330}, {"url": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/10/business/10SPROUT/10SPROUT-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "2104", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "pub_date": "2016-04-10T00:00:00Z", "news_desk": "SundayBusiness", "headline": {"print_headline": "What Went Wrong for \u2018Female Viagra\u2019", "main": "The Female Viagra, Undone by a Drug Maker\u2019s Dysfunction"}, "print_page": "1", "snippet": "Missteps by Valeant, along with aggressive accounting practices and unusual business relationships, derailed one of the most intriguing drugs in a generation.", "_id": "57092d4b38f0d84b5a70611c", "slideshow_credits": null, "abstract": "Future of Addyi, so-called 'female Viagra' approved by Food and Drug Admin to treat low sex drive in women, appears murky following manufacturer Valeant Pharmaceuticals' dismissal of product's entire sales force; drug firm has been besieged with internal problems and severe drop in stock price since it purchased Addyi's owner Sprout Pharmaceuticals for $1 billion in 2015."}